Sort
82,697 grants matching “vaccine development”
Technologies to Advance Next Generation Anthrax Vaccines
$1,025,879Chuck Squires · Pfenex, Inc. · N01 · FY2016 · AI
Tuberculosis Research Unit
$1,025,723W. Henry Boom · Case Western Reserve University · N01 · FY2012 · AI
A Randomized Controlled Trial of Prophylaxis with Direct-acting Antivirals for Kidney Transplantation from Hepatitis C virus-infected donor to Uninfected Recipients (PREVENT-HCV)
$1,025,696Christine Marie Durand · Johns Hopkins University · U01 · FY2022 · AI
Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents
$1,025,685Roy Curtiss · Arizona State University-Tempe Campus · R01 · FY2012 · AI
Recombinant Attenuated Bacterial Vaccines Against Biodefense Agents
$1,025,685Roy Curtiss · Arizona State University-Tempe Campus · R01 · FY2014 · AI
Monoclonal Antibody Therapy for West Nile Virus
$1,025,666Michael S. Diamond · Washington University · U01 · FY2008 · AI
PEDIATRIC AIDS CLINICAL TRIALS UNIT
$1,025,528New York University School Of Medicine · U01 · FY2001 · AI
Deployable, Single-use Device for Single Cell Genomics in Clinical Research
$1,025,490Todd M Gierahn · Honeycomb Biotechnologies, Inc. · R44 · FY2021 · HG
Malaria Transmission Blocking Vaccine Discovery
$1,025,407Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Broad Spectrum Neutralizing Human Abs to SARS and Related Coronaviruses
$1,025,389Wayne A. Marasco · Dana-Farber Cancer Inst · R01 · FY2013 · AI
MECHANISMS OF IMMUNOPATHOLOGY IN DHF/DSS
$1,025,066Univ Of Massachusetts Med Sch Worcester · P01 · FY2002 · AI
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections
$1,024,986Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2024 · AI
Intratumoral immunotherapy with formulated resiquimod for metastatic melanoma
$1,024,973Yen Tun Wang · Curebiotech, Inc. · R44 · FY2019 · CA
Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV
$1,024,945David W Scott · Inhalon Biopharma, Inc. · R44 · FY2025 · AI
IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection
$1,024,942Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2024 · AI
Pharmacokinetics analysis from first-in-human study of IN-002, a potent inhaled muco-trapping antibody therapy for RSV
$1,024,926Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2024 · AI
IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection
$1,024,879Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2025 · AI
Preclinical development of a TriCoil-based nicotine vaccine
$1,024,634Christopher H Clegg · Tria Bioscience Corporation · UH2 · FY2016 · DA
Biophysical constraints of influenza neuraminidase evolution
$1,024,548Nicholas C. Wu · University Of Illinois At Urbana-Champaign · R01 · FY2025 · AI
Development of Pre-Erythrocytic Malaria Vaccines
$1,024,485Robert A Seder · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
#4Corners4Health: A Social Media Cancer Prevention Program for Rural Emerging Adults
$1,024,466David B Buller · Klein Buendel, Inc. · R01 · FY2023 · CA
Human EGFRvIII-specific BiTE for the treatment of Glioblastoma
$1,024,390John H Sampson · Duke University · U01 · FY2016 · NS
Genomic Studies of the Impact of External Factors on Parasite Development and Disease Outcome
$1,024,222Joana Carneiro Da Silva · University Of Maryland Baltimore · U19 · FY2019 · AI
SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections
$1,023,875Jeff T Hutchins · Inhalon Biopharma, Inc. · R44 · FY2025 · AI
Influence of SIV replication on TB progression and immunity
$1,023,452Zandrea Ambrose · University Of Pittsburgh At Pittsburgh · R01 · FY2020 · AI